Literature DB >> 29552284

Competitive endogenous RNA networks: integrated analysis of non-coding RNA and mRNA expression profiles in infantile hemangioma.

Jun Li1, Qian Li1, Ling Chen1, Yanli Gao1, Bei Zhou1, Jingyun Li1.   

Abstract

Infantile hemangioma (IH) is the most common vascular tumour in infants. The pathogenesis of IH is complex and poorly understood. Therefore, achieving a deeper understanding of IH pathogenesis is of great importance. Here, we used the Ribo-Zero RNA-Seq and HiSeq methods to examine the global expression profiles of protein-coding transcripts and non-coding RNAs, including miRNAs and lncRNAs, in IH and matched normal skin controls. Bioinformatics assessments including gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) pathway analyses were performed. Of the 16370 identified coding transcripts, only 144 were differentially expressed (fold change ≥ 2, P ≤ 0.05), including 84 up-regulated and 60 down-regulated transcripts in the IH samples compared with the matched normal skin controls. Gene ontology analysis of these differentially expressed transcripts revealed 60 genes involved in immune system processes, 62 genes involved in extracellular region regulation, and 35 genes involved in carbohydrate derivative binding. In addition, 256 lncRNAs and 142 miRNAs were found to be differentially expressed. Of these, 177 lncRNAs and 42 miRNAs were up-regulated in IH, whereas 79 lncRNAs and 100 miRNAs were down-regulated. By analysing the Ribo-Zero RNA-Seq data in combination with the matched miRNA profiles, we identified 1256 sponge modulators that participate in 87 miRNA-mediated, 70 lncRNA-mediated and 58 mRNA-mediated interactions. In conclusion, our study uncovered a competitive endogenous RNA (ceRNA) network that could further the understanding of the mechanisms underlying IH development and supply new targets for investigation.

Entities:  

Keywords:  infantile hemangioma; lncRNA; mRNA; miRNA; non-coding RNA

Year:  2018        PMID: 29552284      PMCID: PMC5844720          DOI: 10.18632/oncotarget.23946

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Infantile hemangioma (IH) is the most common vascular tumour in childhood, affecting 4% to 5% of infants worldwide [1]. Hemangiomas can show severe progression, which leads to tissue and organ damage that in some cases becomes life-threatening. Clinical treatment varies, including steroids, interferon-alfa, and β-blocker propranolol [2, 3]. However, no definitive therapy is available for IH due to the adverse effects of each drug. The risk factors for IH include preterm birth and placental anomalies [4]. In most cases, IH has a unique clinical course with proliferation and involution phases [5]. Numerous genes involved in IH have been identified. However, the pathogenesis and cause of hemangioma remain largely unknown. The competitive endogenous RNA (ceRNA) hypothesis proposes that RNA transcripts, both coding and non-coding, compete for post-transcriptional control and coregulate each other using microRNA response elements (MREs) [6, 7]. Mounting evidence has shown that long non-coding RNAs and messenger RNAs can function as ceRNAs in diverse physiological and pathophysiological states such as myogenesis, melanoma development and cancer [8-11]. A recent study profiled the expression of distinct long non-coding RNAs (lncRNAs) in infantile hemangioma using microarray analysis and suggested that lncRNAs regulated several genes with important roles in angiogenesis [12]. Endothelial and circulating C19MC microRNAs are biomarkers of infantile hemangioma [13]. Additionally, integrative meta-analysis identified microRNA-regulated networks in infantile hemangioma [14]. However, the role of the ceRNA network in IH has not been elucidated. In this study, we used Ribo-Zero RNA-Seq and HiSeq to examine the global expression profiles of protein-coding transcripts and non-coding RNAs, including miRNAs and lncRNAs, in IH and matched normal skin controls. Subsequently, gene ontology and pathway analysis displayed that, compared with the matched normal skin controls, many processes over-represented in IH were related to immune system processes, extracellular region regulation, and carbohydrate derivative binding. Further ceRNA network analysis identified 1256 sponge modulators including 87 miRNA-mediated, 70 lncRNA-mediated and 58 mRNA-mediated interactions. Our study may help expand understanding of the roles of the transcriptome, particularly non-coding transcripts, in the mechanisms underlying IH development and provide new research directions.

RESULTS

Differential expression profiles and bioinformatics analysis of mRNAs in IH compared with matched normal skin controls

To profile differentially expressed mRNAs, lncRNAs and miRNAs in IH, we performed RNA-seq on 3 IH samples and matched normal skin controls. We used an Illumina HiseqXTen platform (Illumina, San Diego, CA) for sequencing with (2 × 150 bp) the paired-end module. Fold changes (IH vs. matched normal skin controls) and p values were calculated from the normalized expression levels. Hierarchical clustering showed distinguishable mRNA expression patterns among the samples (Figure 1A). Up to 144 mRNAs were differentially expressed in the IH samples compared with the matched normal skin controls (fold change ≥2, P ≤ 0.05; for a list of differentially expressed mRNAs, see Table 1). A total of 84 and 60 mRNAs were up-regulated or down-regulated, respectively, by more than two-fold in IH vs. adjacent normal skin tissues (P < 0.05) (Figure 1B). KEGG Pathway analysis indicated that the chemokine, NF-kappa B and TGF-beta signalling pathways, as well as cell adhesion molecules (CAMs), were mostly found in the IH samples compared with matched normal skin (Figure 1C). In addition, gene ontology (GO) analysis revealed that numerous biological processes, molecular functions and cellular components were involved. Many of the processes that are deregulated in IH were related to immune system processes, carbohydrate derivative binding and extracellular region regulation (Figure 1D).
Figure 1

Expression profiles, Gene ontology (GO) terms and pathways for differentially expressed mRNAs between infantile hemangioma and adjacent normal skin tissues

(A) Hierarchical clustering shows a distinguishable mRNA expression profiling among groups. (B) Volcano analysis exhibit differentially expressed mRNAs. Red dots represent up-regulated genes. Green dots illustrate down-regulated genes. (C) The top 20 pathways that are associated with the coding genes are listed. The enrichment Q value or false discovery rate correct the p value for multiple comparisons. P values are calculated using Fisher’s exact test. The term/pathway on the vertical axis is drawn according to the first letter of the pathway in descending order. The horizontal axis represents the enrichment factor, i.e., (the number of dysregulated genes in a pathway/the total number of dysregulated gene)/(the number of genes in a pathway in the database/the total number of genes in the database). Top 20 enriched pathways are selected according to the enrichment factor value. The selection standards were the number of genes in a pathway ≥4. The different colours from green to red represent the Q value (False discovery rate value). The different sizes of the round shapes represent the gene count number in a pathway. (D) Most enriched GO terms of the three ontologies that are associated with the differentially expressed coding genes are listed. The horizontal axis represents the gene number. The term/GO on the vertical axis is drawn according to the first letter of the GO in descending order. Red bar represents the biological process, blue bar displays the molecular function, and green bar illustrates the cellular component. Norm or Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

Table 1

List of up-regulated and down-regulated mRNAs detected using RNA-seq (FC ≥ 2.83, P < 0.05)

Gene Namelog2(Tum/Ctr)up-or-downP_valueDescription
MPO–6.18461down0.00635myeloperoxidase
MAGEB2–5.44166down0.0158MAGE family member B2
CD8A–3.35204down0.00275CD8a molecule
BPI–3.31652down0.0279bactericidal/permeability-increasing protein
PGLYRP1–3.3111down0.0412peptidoglycan recognition protein 1
LOC283788–3.17651down0.0005FSHD region gene 1 pseudogene
IL18R1–3.02589down5.00E-05interleukin 18 receptor 1
ADCYAP1–2.96929down0.031adenylate cyclase activating polypeptide 1
CXCL13–2.90547down0.02165C-X-C motif chemokine ligand 13
MS4A1–2.78553down0.013membrane spanning 4-domains A1
SERPINB4–2.67117down0.02235serpin family B member 4
MMP12–2.65413down0.02265matrix metallopeptidase 12
PIP–2.63046down0.00195prolactin induced protein
LEFTY2–2.59114down0.0361left-right determination factor 2
IL13RA2–2.54593down0.04385interleukin 13 receptor subunit alpha 2
CSMD3–2.54162down0.00145CUB and Sushi multiple domains 3
OR51E1–2.45263down0.0003olfactory receptor family 51 subfamily E member 1
PTH2R–2.32814down0.03325parathyroid hormone 2 receptor
ADRB3–2.30562down0.0493adrenoceptor beta 3
CCL4L2–2.18575down0.01295C-C motif chemokine ligand 4 like 2
ERAP2–2.14489down5.00E-05endoplasmic reticulum aminopeptidase 2
LTF–2.14431down0.00755lactotransferrin
PADI4–2.08682down0.0333peptidyl arginine deiminase 4
OR51E2–2.0297down0.01705olfactory receptor family 51 subfamily E member 2
FKBP5–1.98625down0.00045FK506 binding protein 5
FOLH1–1.97677down0.0032folate hydrolase (prostate-specific membrane antigen) 1
CD3G–1.862down0.04425CD3g molecule
COL6A5–1.72947down0.0316collagen type VI alpha 5
TUBBP5–1.70945down0.0228tubulin beta pseudogene 5
CLEC4M–1.6691down0.0217C-type lectin domain family 4 member M
S100A9–1.66717down0.0021S100 calcium binding protein A9
DIO3–1.65761down0.009deiodinase, iodothyronine, type III
LOC645752–1.64348down0.0449golgin A6 family member A pseudogene
CD3E–1.61303down0.0266CD3e molecule
TNNT3–1.55491down0.00495troponin T3, fast skeletal type
S100A8–1.53696down0.0022S100 calcium binding protein A8
FUT9–1.50479down0.00195fucosyltransferase 9
KRT311.50307up0.02565keratin 31
KRTAP11-11.51562up0.00975keratin associated protein 11-1
KRT851.51808up0.01765keratin 85
KRT811.54671up0.0292keratin 81
KRT341.54769up0.03615keratin 34
EPSTI11.574up0.0017epithelial stromal interaction 1 (breast)
IFI61.57562up0.0033interferon alpha inducible protein 6
IFI351.59026up0.0059interferon induced protein 35
KRTAP3-21.61219up0.0107keratin associated protein 3-2
KC61.62074up0.0318keratoconus gene 6
KRT831.65762up0.0203keratin 83
OAS31.69667up0.001052'-5'-oligoadenylate synthetase 3
USP181.72046up0.00215ubiquitin specific peptidase 18
CYP26B11.74162up0.00045cytochrome P450 family 26 subfamily B member 1
LNX1-AS21.74788up0.022LNX1 antisense RNA 2
IFI441.75064up0.00015interferon induced protein 44
TNFRSF41.75918up0.0375tumor necrosis factor receptor superfamily member 4
LOC3399751.76055up0.02065uncharacterized LOC339975
CLDN111.7733up0.012claudin 11
KRT351.78149up0.0024keratin 35
KRT33A1.80012up0.00445keratin 33A
OAS21.83729up0.001452'-5'-oligoadenylate synthetase 2
KRT861.85155up0.0094keratin 86
DCD1.85338up0.0401dermcidin
ACAN1.85416up0.0002aggrecan
PKD1L21.90338up0.0378polycystin 1 like 2 (gene/pseudogene)
SCGB1B2P1.91013up0.01375secretoglobin family 1B member 2, pseudogene
CMPK21.92066up0.00015cytidine/uridine monophosphate kinase 2
ADAMTS181.95193up0.0003ADAM metallopeptidase with thrombospondin type 1 motif 18
KRT33B1.9594up0.0128keratin 33B
IFIT11.97285up0.0001interferon induced protein with tetratricopeptide repeats 1
MX11.99777up0.00015MX dynamin like GTPase 1
RSAD22.07171up5.00E-05radical S-adenosyl methionine domain containing 2
IFI44L2.31465up5.00E-05interferon induced protein 44 like
LINC004872.42803up0.0367long intergenic non-protein coding RNA 487
ISG152.47094up5.00E-05ISG15 ubiquitin-like modifier
SULT1A22.52975up0.02025sulfotransferase family 1A member 2
DMC12.61725down0.00415DNA meiotic recombinase 1
FAM132B2.69101up0.0118-
NRIR2.97361up0.0399negative regulator of interferon response (non-protein coding)
MTHFD2P13.49824up0.01845methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase pseudogene 1
OR8B24.67189up0.0423olfactory receptor family 8 subfamily B member 2
LOC1019291284.88337up0.0419uncharacterized LOC101929128

Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

Expression profiles, Gene ontology (GO) terms and pathways for differentially expressed mRNAs between infantile hemangioma and adjacent normal skin tissues

(A) Hierarchical clustering shows a distinguishable mRNA expression profiling among groups. (B) Volcano analysis exhibit differentially expressed mRNAs. Red dots represent up-regulated genes. Green dots illustrate down-regulated genes. (C) The top 20 pathways that are associated with the coding genes are listed. The enrichment Q value or false discovery rate correct the p value for multiple comparisons. P values are calculated using Fisher’s exact test. The term/pathway on the vertical axis is drawn according to the first letter of the pathway in descending order. The horizontal axis represents the enrichment factor, i.e., (the number of dysregulated genes in a pathway/the total number of dysregulated gene)/(the number of genes in a pathway in the database/the total number of genes in the database). Top 20 enriched pathways are selected according to the enrichment factor value. The selection standards were the number of genes in a pathway ≥4. The different colours from green to red represent the Q value (False discovery rate value). The different sizes of the round shapes represent the gene count number in a pathway. (D) Most enriched GO terms of the three ontologies that are associated with the differentially expressed coding genes are listed. The horizontal axis represents the gene number. The term/GO on the vertical axis is drawn according to the first letter of the GO in descending order. Red bar represents the biological process, blue bar displays the molecular function, and green bar illustrates the cellular component. Norm or Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue. Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

Bioinformatics analysis of lncRNAs in IH compared with matched normal skin controls

Using the Gencode, RefSeq and UCSC Knowngene databases for non-coding transcripts, we identified 256 differentially expressed lncRNAs with greater than two-fold changes in IH and p values < 0.05 (Figure 2A). Of these, 177 were overexpressed and 79 were underexpressed in IH relative to the matched normal skin controls (fold change ≥ 2, P ≤ 0.05; for a list of differentially expressed lncRNAs, see Table 2). LncRNAs (long non-coding RNAs), are defined as greater than 200 nucleotides in length, transcribed by RNA polymerase II (RNA PII), and lacking an open reading frame [15]. LncRNAs have been found to regulate protein-coding (pc) gene expression at both the transcriptional and post-transcriptional levels [16]. To identify the potential mRNA targets of lncRNAs, we use RNAplex to predict the binding of lncRNAs with the antisense target mRNAs. mRNAs 10 kb upstream or downstream of lncRNAs were considered to be the conceivable lncRNA targets and defined as cis target mRNAs. Gene ontology (GO) analysis revealed that cis target mRNAs of differentially expressed lncRNAs were mostly involved in regulatory mechanisms related to transcription, nucleic acid binding transcription factor activity and intracellular components (Figure 2B). KEGG Pathway analysis indicated that the MAPK signalling pathway, regulation of autophagy and metabolic pathways were implicated for the cis target mRNAs of differentially expressed lncRNAs (Figure 2C).
Figure 2

Gene ontology (GO) terms and pathways for target mRNAs of differentially expressed lncRNAs between infantile hemangioma and adjacent normal skin tissues

(A) Hierarchical clustering shows a distinguishable lncRNA expression profiling among groups. (B) Most enriched GO terms of the three ontologies that are associated with the cis target mRNAs of differentially expressed lncRNAs are listed. (C) The top 20 pathways that are associated with the cis target mRNAs of differentially expressed lncRNAs are listed. (B) The horizontal axis represents the gene number. The term/GO on the vertical axis is drawn according to the first letter of the GO in descending order. Red bar represents the biological process, blue bar displays the molecular function, and green bar illustrates the cellular component. (C) The enrichment Q value or false discovery rate correct the p value for multiple comparisons. P values are calculated using Fisher’s exact test. The term/pathway on the vertical axis is drawn according to the first letter of the pathway in descending order. The horizontal axis represents the enrichment factor, i.e., (the number of dysregulated genes in a pathway/the total number of dysregulated gene)/(the number of genes in a pathway in the database/the total number of genes in the database). Top 20 enriched pathways are selected according to the enrichment factor value. The selection standards were the number of genes in a pathway ≥4. The different colours from green to red represent the Q value (False discovery rate value). The different sizes of the round shapes represent the gene count number in a pathway. Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

Table 2

List of up-regulated and down-regulated lncRNAs detected using RNA-seq (FC ≥ 2.83, P < 0.05)

LncRNAIDGenePoslog2 (Tum/Ctr)up-or-downp_valueLncRNA GeneID
TCONS_00116532chr5:101515283-101519050–2.74762down0.0153XLOC_074583
TCONS_00049881chr16:76805140-76807266–2.74208down0.03405XLOC_031473
TCONS_00140157chr8:111620546-111622506–2.65655down0.02805XLOC_090179
TCONS_00108080chr4:97512593-97516549–2.51518down0.03695XLOC_068366
TCONS_00049878chr16:76790731-76793194–2.36369down0.0245XLOC_031470
TCONS_00116531chr5:101510927-101514253–2.31673down0.03415XLOC_074582
TCONS_00125444chr6:77144877-77146646–2.19865down0.0304XLOC_080698
TCONS_00047386chr15:95209116-95212765–1.62607down0.04695XLOC_030120
TCONS_00099093chr3:117310248-1173156621.60464up0.026XLOC_061648
TCONS_00094390chr3:115548706-1155549141.63654up0.045XLOC_058344
TCONS_00112159chr5:104342703-1043465811.6409up0.0436XLOC_071442
TCONS_00099090chr3:117295535-1173048611.65949up0.0244XLOC_061645
TCONS_00125869chr6:92532111-925395011.72153up0.01895XLOC_081015
TCONS_00092337chr3:21220256-212266641.73612up0.01655XLOC_056961
TCONS_00036940chr13:105981280-1059998401.8649up0.0291XLOC_023137
TCONS_00022826chr11:26799455-268027521.995up0.04175XLOC_013761
TCONS_00092345chr3:21256300-212624132.01955up0.0065XLOC_056969
TCONS_00125870chr6:92539642-925427652.05275up0.0118XLOC_081016
TCONS_00144439chr9:13841053-138435432.11565up0.04215XLOC_093201
TCONS_00132673chr7:94029530-940360982.1175up0.03365XLOC_085154
TCONS_00088818chr22:11878998-118805402.12569up0.04895XLOC_054900
TCONS_00099084chr3:117263272-1172652492.13489up0.0322XLOC_061639
TCONS_00089156chr22:23536916-235487762.23141up0.00335XLOC_055095
TCONS_00112938chr5:136193267-1361963872.2618up0.03135XLOC_072057
TCONS_00093724chr3:76746891-767483742.30541up0.02505XLOC_057834
TCONS_00021543chr11:124180846-1241864712.31143up0.04245XLOC_012894
TCONS_00099092chr3:117307664-1173095822.31645up0.0351XLOC_061647
TCONS_00077659chr2:12602918-126061492.33745up0.02735XLOC_047338
TCONS_00106552chr4:19193285-191982982.3654up0.02555XLOC_067212
TCONS_00109906chr4:187247968-1872498252.40602up0.02915XLOC_069754
TCONS_00106583chr4:19283454-192883992.44245up0.0258XLOC_067243
TCONS_00142894chr8:98381305-983825302.46222up0.04195XLOC_092151
TCONS_00092347chr3:21263525-212652952.50214up0.0228XLOC_056971
TCONS_00126048chr6:104495681-1044979082.57552up0.04765XLOC_081156
TCONS_00021618chr11:124429567-1244332672.6993up0.00985XLOC_012968
TCONS_00142579chr8:89240840-892418982.72566up0.0405XLOC_091914
TCONS_00116213chr5:86348589-863515503.02011up0.0077XLOC_074350
TCONS_00013577chr10:64133769-641348773.14074up0.04865XLOC_008097
TCONS_00021614chr11:124419031-1244230633.17524up0.02925XLOC_012964
TCONS_00138013chr8:9196728-92034763.31685up0.04465XLOC_088644
TCONS_00117017chr5:130223107-1302257003.34741up0.0088XLOC_074967
TCONS_00032295chr12:91627173-916316033.74738up0.0054XLOC_019826
TCONS_00116260chr5:86539574-865473713.90234up0.00265XLOC_074397
TCONS_00116261chr5:86548066-865521264.02636up0.004XLOC_074398
TCONS_00032240chr12:91452883-914559614.05433up0.00415XLOC_019771
TCONS_00087133chr21:38178744-381819004.62793up0.04685XLOC_053685
TCONS_00116241chr5:86436761-864479305.05555up0.00105XLOC_074378

Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

Gene ontology (GO) terms and pathways for target mRNAs of differentially expressed lncRNAs between infantile hemangioma and adjacent normal skin tissues

(A) Hierarchical clustering shows a distinguishable lncRNA expression profiling among groups. (B) Most enriched GO terms of the three ontologies that are associated with the cis target mRNAs of differentially expressed lncRNAs are listed. (C) The top 20 pathways that are associated with the cis target mRNAs of differentially expressed lncRNAs are listed. (B) The horizontal axis represents the gene number. The term/GO on the vertical axis is drawn according to the first letter of the GO in descending order. Red bar represents the biological process, blue bar displays the molecular function, and green bar illustrates the cellular component. (C) The enrichment Q value or false discovery rate correct the p value for multiple comparisons. P values are calculated using Fisher’s exact test. The term/pathway on the vertical axis is drawn according to the first letter of the pathway in descending order. The horizontal axis represents the enrichment factor, i.e., (the number of dysregulated genes in a pathway/the total number of dysregulated gene)/(the number of genes in a pathway in the database/the total number of genes in the database). Top 20 enriched pathways are selected according to the enrichment factor value. The selection standards were the number of genes in a pathway ≥4. The different colours from green to red represent the Q value (False discovery rate value). The different sizes of the round shapes represent the gene count number in a pathway. Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue. Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

Differential expression and bioinformatics analysis of miRNAs in IH compared with matched normal skin controls

We also determines the miRNA expression profiles between IH and matched normal skin controls using HiSeq. One hundred forty-two miRNA candidates were found to be differentially expressed (fold change ≥ 2, P ≤ 0.05; for a list of differentially expressed miRNAs, see Table 3). Of these, 42 miRNAs were up-regulated in IH, whereas 100 miRNAs were down-regulated (Figure 3A). To examine the potential biological functions of the miRNAs of interest in IH, we use miRanda, targetscan and PITA software to identify the target genes of known miRNAs with differential expression profiles and extracted intersections or unions of target genes as the final prediction result. Gene ontology (GO) analysis revealed that the target mRNAs of differentially expressed miRNAs were mostly involved in cellular processes, cell components and binding (Figure 3B).
Table 3

List of up-regulated and down-regulated miRNAs detected using small RNA-seq (FC ≥ 2.83, P < 0.05)

miR_namefold-change(log2 Tum/Ctr)up-or-downp_valuesig-lable
hsa-miR-9-3p–7.10538475down0.000122742**
hsa-miR-1303–6.86430997down0.000490585**
hsa-miR-223-3p–3.53749571down1.65E-266**
hsa-miR-509-3-5p–3.49076386down4.54E-10**
hsa-miR-509-5p–2.50137905down0.00149862**
hsa-miR-450a-2-3p–2.22132264down0.007574552**
hsa-miR-337-5p–2.13638952down0.000918863**
hsa-miR-135a-5p–2.11442989down0.012782924*
hsa-miR-513c-5p–2.11442989down0.012782924*
hsa-miR-2355-3p–2.08634155down0.004368201**
hsa-miR-202-5p–1.99889374down0.007235532**
hsa-miR-200c-5p–1.99886536down0.021358055*
hsa-miR-664b-3p–1.99886536down0.021358055*
hsa-miR-3648–1.93753391down0.001441353**
hsa-miR-429–1.93708866down1.47E-256**
hsa-miR-26a-1-3p–1.92492452down0.004102228**
hsa-miR-3611–1.92492452down0.004102228**
hsa-miR-187-3p–1.89198508down0.000828053**
hsa-miR-664a-3p–1.87801528down1.82E-41**
hsa-miR-383-5p–1.87335512down0.03528718*
hsa-miR-335-3p–1.84083467down7.07E-87**
hsa-miR-203a-3p–1.72913403down0**
hsa-miR-3912-3p–1.71155782down2.01E-06**
hsa-miR-183-3p–1.69939239down0.031012226*
hsa-miR-135b-5p–1.69929888down3.86E-09**
hsa-miR-141-5p–1.69460943down6.85E-21**
hsa-miR-377-5p–1.65878433down7.03E-08**
hsa-miR-16-5p–1.65065115down0**
hsa-miR-150-5p–1.62494834down2.07E-49**
hsa-miR-627-5p–1.6233869down0.000309094**
hsa-miR-6510-3p–1.58388025down0.000271487**
hsa-miR-548p–1.58387326down0.026725738*
hsa-miR-203b-3p–1.58383438down1.74E-09**
hsa-miR-195-5p–1.5823761down0**
hsa-miR-141-3p–1.5772266down0**
hsa-miR-200b-3p–1.57584304down0**
hsa-miR-944–1.5589637down4.65E-10**
hsa-miR-200b-5p–1.53135387down2.72E-13**
hsa-miR-31-5p–1.5239109down6.16E-159**
hsa-miR-183-5p–1.52252398down2.78E-140**
hsa-miR-92a-1-5p–1.52249641down0.007046614**
hsa-miR-493-5p–1.51904529down6.20E-36**
hsa-miR-320d1.58604035up0.004519782**
hsa-miR-524-3p1.69892552up4.81E-139**
hsa-miR-77041.8311765up0.000268926**
hsa-miR-450a-1-3p2.00090764up0.021183756*
hsa-miR-185-5p2.03429793up1.64E-39**
hsa-miR-503-5p2.10316253up1.37E-29**
hsa-miR-122-5p2.13865463up0.00090565**
hsa-miR-1-3p2.40555691up2.02E-13**
hsa-miR-7-5p2.40555691up2.02E-13**
hsa-miR-520e2.41594514up0.002562365**
hsa-miR-1269b3.39374391up3.56E-05**
hsa-miR-1268a3.8087166up0.000515933**
hsa-miR-1268b3.8087166up0.000515933**

Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

Figure 3

Expression profiles of differentially expressed miRNAs and Gene ontology (GO) terms for target mRNAs of differentially expressed miRNAs between infantile hemangioma and adjacent normal skin tissues

(A) Scatter plot shows the differentially expressed miRNAs. Red dots represent up-regulated miRNAs. Green dots illustrate down-regulated miRNAs. (B) Most enriched GO terms of the three ontologies that are associated with the target mRNAs of differentially expressed miRNAs are listed. The term/GO on the horizontal axis is drawn according to the first letter of the GO in ascending order from left to right. The vertical axis represents the percent of genes and gene number. Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

Expression profiles of differentially expressed miRNAs and Gene ontology (GO) terms for target mRNAs of differentially expressed miRNAs between infantile hemangioma and adjacent normal skin tissues

(A) Scatter plot shows the differentially expressed miRNAs. Red dots represent up-regulated miRNAs. Green dots illustrate down-regulated miRNAs. (B) Most enriched GO terms of the three ontologies that are associated with the target mRNAs of differentially expressed miRNAs are listed. The term/GO on the horizontal axis is drawn according to the first letter of the GO in ascending order from left to right. The vertical axis represents the percent of genes and gene number. Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

Real-time quantitative PCR validation

To validate the RNA-seq data, we randomly selected 9 differentially expressed RNAs (bold-face type in Tables 1–3). Real-time quantitative PCR (qRT-PCR) and Bulge-Loop™ qRT-PCR analyses were performed on an additional 9 independent IH skin samples (Table 4). The results revealed that similar up-regulation or down-regulation patterns were observed in both the RNA-seq and qRT-PCR samples for the 9 RNAs (Figure 4, bold in Tables 1–3). Therefore, our RNA-seq data were reliable and stable. Among the 9 RNAs, IFI44L, ISG15, TCONS_00088818, TCONS_000112159, TCONS_000125870, miR-503-5p and miR-524-3p were all expressed to a greater extent in the IH tissues than in the matched normal skin controls.
Table 4

Demographic and clinical characteristics of infantile hemangioma (IH) patients (capillary hemangioma)

No.AgeGenderPositionPathologySample use
13 months 8 daysMaleLeft axillaIHRNA-seq
27 months 5 daysFemaleHeadIHRNA-seq
312 monthsFemaleLeft AbdomenIHRNA-seq
49 monthsFemaleRight thoracic wallIHqRT-PCR
55 monthsMaleThoracic wallIHqRT-PCR
66 months 9 daysFemaleOcciputIHqRT-PCR
78 months 13 daysFemaleRight posterior neckIHqRT-PCR
810 monthsFemaleLeft abdomenIHqRT-PCR
94 monthsFemaleRight thoracic wallIHqRT-PCR
1011 monthsMaleThoracic wallIHqRT-PCR
118 months 21 daysFemaleOcciputIHqRT-PCR
125 months 12 daysFemaleHeadIHqRT-PCR
Figure 4

The differential expression of mRNAs, lncRNAs and miRNAs between additional IH skin (n = 9) and matched normal skin tissues (n = 9)

mRNAs and lncRNAs expression were validated by quantitative real-time PCR using 2(–△△Ct) method. miRNAs expression was validated by Bulge-Loop™ qRT-PCR. *P < 0.05, **P < 0.01.

The differential expression of mRNAs, lncRNAs and miRNAs between additional IH skin (n = 9) and matched normal skin tissues (n = 9)

mRNAs and lncRNAs expression were validated by quantitative real-time PCR using 2(–△△Ct) method. miRNAs expression was validated by Bulge-Loop™ qRT-PCR. *P < 0.05, **P < 0.01.

The ceRNA network construction

Recently, lncRNAs and mRNAs have been demonstrated to be function as ceRNAs in diverse physiological and pathophysiological states. It is known that mRNAs or lncRNAs can bind miRNAs through microRNA response elements (MREs). Therefore, we use rna22 and targetscan to screen the lncRNAs and mRNAs with MREs. To ascertain the associations of differentially expressed lncRNAs and miRNAs with mRNAs, based on the 142 differentially expressed miRNAs, 144 differentially expressed mRNAs, and 256 differentially expressed lncRNAs, an lncRNA-miRNA-mRNA correlation network was constructed (Figure 5). The network displayed the associations among 87 miRNAs, 70 lncRNAs and 58 mRNAs mediated interactions. For example, miR-26a-1-3p could bind to lncRNAs TCONS_00074621 and mRNA CD24, miR-24-3p bind with TCONS_00000006 and LEFTY2, moreover, miR-514a-3p bind to TCONS_00040753 and FLT1. As shown in Figure 5, one miRNA was associated with one to tens of mRNAs and vice versa. One lncRNA was related to one to tens of miRNAs. In total, 1256 sponge modulators participated in 87 miRNA-mediated, 70 lncRNA-mediated and 58 mRNAs’ transcripts-mediated interactions. These findings indicated that the expression profiles of miRNAs, mRNAs and lncRNAs were significantly correlated.
Figure 5

The ceRNA network of the differentially expressed miRNA-mediated lncRNAs and mRNAs interactions

Red color represents the mRNA name, green color displays the lncRNA name, and orange color illustrates the miRNA name. Taken TCONS_00126150 | CD24 and TCONS_00126153 | CD24 as an example, the TCONS_ number before | means the ID number of each transcript, one gene has many transcripts.

The ceRNA network of the differentially expressed miRNA-mediated lncRNAs and mRNAs interactions

Red color represents the mRNA name, green color displays the lncRNA name, and orange color illustrates the miRNA name. Taken TCONS_00126150 | CD24 and TCONS_00126153 | CD24 as an example, the TCONS_ number before | means the ID number of each transcript, one gene has many transcripts.

DISCUSSION

Currently, with the advent of next-generation sequencing technologies, RNA-Seq is gradually replacing microarrays for the detection of transcript expression profiling. IH is one of the most common tumors diagnosed in young children. The pathogenesis of hemangioma is largely unknown due to its sophisticated etiology. Although a lot of papers report the RNA networks in IH [12, 14, 17–19], those work all used microarrays methods. In this study, we used Ribo-Zero RNA-Seq and HiSeq means to examine the global expression profiles of protein-coding transcripts and non-coding RNAs, including miRNAs and lncRNAs, in IH and matched normal skin controls. Totally, 144 mRNAs, 256 lncRNAs and 142 miRNAs were found to be differentially expressed (fold change ≥ 2, P ≤ 0.05) in IH compared to matched normal skin. Further integrated ceRNA network analysis revealed that 353 sponge modulators participate in 39 miRNA, 29 lncRNA and 147 mRNA mediated interactions. Competitive endogenous (ce) RNAs cross-regulate each other through sequestration of shared microRNAs and form complex regulatory networks based on their microRNA signatures [20]. Genome-wide transcriptional profiling of vessels from proliferating and involuting hemangiomas has been used to identify differentially expressed genes [19]. A lncRNA microarray study reported that a large number of genes are differentially expressed in IH [12]. Integrative meta-analysis identifies miRNA-regulated networks in IH [14]. Here, based on RNA-seq technology, using IH tissues and matched normal skin, we presented a new ceRNA network that determined the functions of particular miRNAs, lncRNAs and mRNAs in IH development (Figure 5). Alterations in one ceRNA may have striking effects on the integrated ceRNA and transcriptional networks. Taken miR-664a-3p as an example, it was down-regulated in IH tissues from the small RNA-seq data (Table 3). Bulge-Loop™ qRT-PCR demonstrated that expression of miR-664a-3p was decreased in another nine IH tissues (Figure 4). The ceRNA network analysis revealed that three lncRNAs TCONS_00020616, TCONS_00058199 and TCONS_00108595 could bind to miR-664a-3p. Moreover, nine mRNAs including ADCYAP1, CSMD3, IL18R1, IKZF3, CD8A, FGL2, FUT9, IGF2BP1, and TMEM38B were predicted to bind with miR-664a-3p (Figure 5). This ceRNA network indicated that those nine mRNAs’ expression could be regulated by miR-664a-3p, and three lncRNAs TCONS_00020616, TCONS_00058199, TCONS_00108595 could compete to bind with miR-664a-3p and then affect those nine mRNAs’ expression. The pathogenesis of IH has been linked to pathways affecting angiogenesis and vasculogenesis [21]. Those microarray analyses concluded that angiogenin may be a useful serum marker for hemangiomas [22], IH endothelial cells (HEMECs) reflects a pro-proliferative cell type with altered adhesive characteristics [17], proliferating hemangiomas display increased expression of genes involved in endothelial-pericyte interactions, as well as those involved in neural and vascular patterning [19], lncRNAs likely regulate several genes in angiogenesis [12], miRNA-mRNA expression networks display that deregulated genes play roles in cell growth and differentiation, cell signaling, angiogenesis and vasculogenesis [14]. In the present study, using RNA-seq technology, we found that deregulated mRNAs related to immune system processes, carbohydrate derivative binding, extracellular region regulation, chemokine, NF-kappa B and TGF-beta signalling pathways, as well as cell adhesion molecules (CAMs) (Figure 1). Moreover, cis target mRNAs of differentially expressed lncRNAs were mostly involved in regulatory mechanisms related to transcription, nucleic acid binding transcription factor activity, intracellular components, MAPK signalling pathway, regulation of autophagy and metabolic pathways (Figure 2). Additionally, target mRNAs of differentially expressed miRNAs were mostly involved in cellular processes, cell components and binding (Figure 3). These results are partly consistent with those of previous studies in that CAMs are involved. Besides, RNA-seq data show some new findings in that regulation of autophagy and metabolic pathways, TGF-beta, NF-kappa B signalling and chemokine signalling were involved in the pathogenesis of IH. Endothelial TGF-β signalling has been implicated in the regulation of angiogenesis [23]. Expression of NF-kappa B target genes was demonstrated in proliferating IH. Targeting NF-kappa B in infantile hemangioma-derived stem cells reduced VEGF-A expression [24]. The chemokine CXCL-14 has been reported to be involved in the occurrence and development of infantile hemangioma [25]. Our RNA-seq data found that TGF-beta, NF-kappa B signalling and chemokine signalling were involved in the pathogenesis of IH. The results are consistent with those of previous studies, which suggested that the RNA-seq data are reliable. By carefully comparing our data with other’s, IGF2, FOXF1 and EGFL7 were reported to be up-regulated in IH, FOXC1 and EGFR were down-regulated in IH [12]. In this study, we found that IGF2 mRNA-binding proteins (IGF2BPs) including IGF2BP1, IGF2BP2 and IGF2BP3 were all downregualted in IH. Although recent publication reported that results obtained by RNA-seq and microarrays were highly reproducible [26], some discrepancy may be existed in the differentially expressed RNAs. Therefore, further demonstrating the function of particular RNA in IH development is urgently needed. In addition, larger samples are needed to perform receiver operating characteristic (ROC) curve analysis to prove that some of the IH RNAs are promising biomarkers. Taken together, understanding the functional interactions among lncRNAs, miRNAs and mRNAs could lead to new explanations for IH disease pathogenesis [7]. Further elucidating the underlying mechanisms of the functions of miRNAs, lncRNAs and mRNAs in IH would be helpful in revealing the biological aetiology and potentially provide useful information for IH evaluation and treatment.

MATERIALS AND METHODS

Ethics statement

This study was approved by the Medical Ethics Committee of the Obstetrics and Gynaecology Hospital affiliated with Nanjing Medical University (No. [2015] 91). Children with IH underwent surgery at out hospital. The IH samples and matched normal skin controls were collected from patients who underwent surgery and whose parents provided written consent.

Tissue samples

Proliferating capillary infantile hemangioma (IH) and matched normal skin tissues were obtained from 12 different patients who were admitted to the Obstetrics and Gynaecology Hospital affiliated with Nanjing Medical University for IH removal. Patient information is listed in Table 4. A diagnosis of proliferative infantile hemangioma was confirmed by routine pathological examination. The collected skin samples were immediately frozen in liquid nitrogen for total RNA preparation.

Total RNA isolation

Total RNA was extracted from biopsy samples using the Qiagen RNeasy mini kit (Qiagen, Valencia, CA). After ribosomal RNA depletion, RNA-seq libraries were prepared using ScriptSeq complete kits from Epicenter (Madison, WI). RNA purity was assessed using the Nano Photometer® spectrophotometer (IMPLEN, CA, USA), and RNA concentration was measured using the Qubit® RNA Assay Kit in Qubit® 2.0 Flurometer (Life Technologies, CA, USA). RNA integrity was assessed using the RNA Nano 6000 Assay Kit from the Bioanalyser 2100 system (Agilent Technologies, CA, USA).

Library preparation, quality examination and sequencing for mRNAs and lncRNAs

The sequencing libraries were prepared following manufacturer recommendations from the VAHTS™ Total RNA-seq (H/M/R) Library Prep Kit for Illumina®. The details of library construction were patented by the company (Vazyme, China). After cluster generation, the libraries were sequenced on an Illumina Hiseq X10 platform, and 150-bp paired-end reads were generated. Raw reads in fastq format were first processed using in-house perl scripts. Clean reads were obtained by removing reads with adapters, reads in which unknown bases were more than 5% and low quality reads (if the percentage of low quality bases was greater than 50% in a given read, we defined the low quality base to be the base whose sequencing quality was no more than 10). At the same time, Q20, Q30, and GC contents were calculated for the clean reads. All downstream analyses were based on the clean reads. The reference genome and gene model annotation files were downloaded directly from the genome website. The reference genome index was built using Bowtie (v2.1.0) [27], and the paired-end clean reads were aligned to the reference genome using TopHat (v2.1.1) [28].

Transcriptome assembly, lncRNA prediction and target gene prediction

The mapped reads from each sample were assembled using Cufflinks (v2.2.1) [29] with a reference-based approach. Cufflinks uses a probabilistic model to simultaneously assemble and quantify the expression levels of a minimal set of isoforms, which provides a maximum likelihood explanation of the expression data in a given locus. Then, Cuffmerge was used to merge these sample assemblies into a master transcriptome, which was compared to known transcripts via Cuffcompare. The lncRNAs were predicted by several strict steps based on RNA structural characteristics and non-coding properties. The steps were as follows: 1) transcripts, not in any class code of “ j, i, o, u, x ”, were filtered out; 2) transcripts shorter than 200 bp were filtered out; 3) transcripts aligned to sequences in the NONCODE database [30] by blastn were identified as known lncRNAs; 4) the retained transcripts (known lncRNAs were not included) were used to predict protein coding potential by Coding Potential Calculator (CPC) [31] and TransDecoder (http://transdecoder.github.io/), transcripts with coding potential were removed, and those without coding potential were identified as novel lncRNAs. The known lncRNAs and novel lncRNAs were together used for subsequent analyses. LncRNAs can negatively or positively affect expression of the downstream gene via an upstream noncoding promoter. Genes within 10 kb upstream or downstream of lncRNAs were abstracted by bedtools (http://bedtools.readthedocs.io/en/latest/) as lncRNA target genes. However, antisense lncRNAs can regulate overlapping sense transcripts. Transcripts that overlapped with LncRNAs on the opposite strand were also identified as lncRNA target genes, and the interactions between lncRNAs and transcripts were revealed by RNAplex [32].

Quantification of gene expression levels and differential expression analysis

Cuffdiff (v2.2.1) [33] was used to calculate FPKMs for both lncRNAs and coding genes in each group. Gene FPKMs were computed by summing the FPKMs of the transcripts in each gene group. FPKM stands for “fragments per kilobase of exon per million fragments mapped” and is calculated based on the length of the fragments and the reads count mapped to each fragment. Cuffdiff (v2.2.1) provides statistical routines for determining differential expression in digital transcripts or gene expression datasets using a model based on a negative binomial distribution. Transcripts or genes with corrected p values less than 0.05 and absolute values of log2 (fold change) <1 were classified as significantly differentially expressed.

Small RNA sequencing and bioinformatics analysis

Total RNA was separated by 15% agarose gels to extract the small RNA (18–30 nt). After ethanol precipitation and centrifugal enrichment of small RNA samples, the library was prepared according to the methods and processes described in the Small RNA Sample Preparation Kit (Illumina, RS-200-0048). Insert size was assessed using the Agilent Bioanalyser 2100 system (Agilent Technologies, CA, USA), and after the insert size was consistent with expectations, qualified insert size was accurately quantitated using a Taqman fluorescence probe from the AB Step One Plus Real-Time PCR system (Library valid concentration > 2 nM). The qualified libraries were sequenced using an Illumina Hiseq 2500 platform, and 50-bp single-end reads were generated. First, the tags were mapped to the reference genome by SOAP [34] to analyse their distributions within the genome and were aligned to the miRBase database [35] using blast. The tags were identified as known miRNAs when they satisfied the following criteria: 1) there were no mismatches when aligned to the miRNA precursors in the miRBase database; 2) based on the first criteria, the tags were aligned to the mature miRNAs in the miRBase database with at least 16-nt overlap while allowing offsets. The miRNA target genes were predicted using two software programs (targetscan and miRanda) as we previously described [36], and the intersection of target genes (the intersections were the same target genes of the same miRNAs) were the final target genes. The miRNA expression levels were measured by “Transcripts Per Kilobase Million” (TPM).where C is the read count of a miRNA and L is the total count of clean reads in sample. Differentially expressed miRNAs were evaluated using the following statistical tests: 1) Statistical algorithm developed by Audic and Claverie (1997) [37]where N1 is the total clean reads from sample 1, N2 is the total clean reads from sample 2, x is the number of reads from sample 1 mapped to miRNA A and y is the number of reads from sample 2 mapped to miRNA A.

Gene Ontology (GO) and KEGG enrichment analysis

GO enrichment analysis of differentially expressed genes or target genes of differentially expressed lncRNAs was implemented using a perl module (GO::TermFinder) [38]. GO terms with corrected p values less than 0.05 were considered to be significantly enriched among the differentially expressed genes or the target genes of differentially expressed lncRNAs. R functions (phyper and qvalue) were used to test for statistical enrichment of the differentially expressed genes or target genes of the differentially expressed lncRNAs among the KEGG pathways. KEGG pathways with corrected p values less than 0.05 were considered to be significantly enriched among the differentially expressed genes or the target genes of the differentially expressed lncRNAs.

Validation of RNA-seq data

To confirm the RNA-seq data, the expression profiles of randomly selected mRNAs and lncRNAs were tested in another 9 IH patients using quantitative real-time polymerase chain reactions (qRT-PCR) with the SYBR green method on an Applied Biosystems ViiA™ 7 Dx (Life Technologies, USA). Patient information is listed in Table 4. The sequences of the specific PCR primer sets used for qRT-PCR are listed in Table 5. The RNA expression levels were normalized to the internal control gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), using the 2(–△△Ct) method as we previously described [39]. Three selected miRNAs were further examined by Bulge-Loop™ qRT-PCR according to the manufacturer’s protocol (RIBOBIO, Guangzhou, China) with the SYBR green method on an Applied Biosystems ViiATM 7 Dx (Life Technologies, USA). The miRNA expression levels were normalized to u6 (RIBOBIO, Guangzhou, China), using the 2(–△△Ct) method.
Table 5

Details of primer pairs used in analysis of mRNAs and lncRNAs expression by qRT-PCR

Gene nameForward primer (5′-3′)Reverse primer (5′-3′)
IFI44LACAGAGCCAAATGATTCCCTATGTCGATAAACGACACACCAGTTG
ISG15CGCAGATCACCCAGAAGATCGTTCGTCGCATTTGTCCACCA
PIPGTCAGTACGTCCAAATGACGAACTGTTGGTGTAAAAGTCCCAGT
TCONS_00088818GCCTTGTGGTGTCTCCTCAGTAGACCAGGCGTCATAGCAGAA
TCONS_00112159GAAACAGCCACGGAGGGAACGATTTCTGCAATGCCGTGCC
TCONS_00125870CCTAGAACCAGGGGCCACAATTTGCTGGGCACTCTGTAGC

CeRNA network analysis

The miRanda and TargetScan assessments were used to identify ceRNAs (competing endogenous RNAs, including protein-coding messenger RNAs, long non-coding RNAs and circular RNAs), containing microRNA response elements (MREs). Then, ceRNAs with common miRNAs were selected to predict the global interactions between miRNAs and ceRNAs. Additionally, the ceRNAs with common miRNAs that were up- or down-regulated by miRNAs were abstracted based on differential expression to predict the co-regulated interactions of miRNAs and ceRNAs. The co-regulated ceRNA network was generated by Cytoscape (V. 3.4.0) [40].

Statistical analysis

Data were analysed using the SPSS 20.0 software package (SPSS, Chicago, IL, USA) with an independent-samples T test performed between the two groups. All values are represented as the mean ± standard deviation (SD) from at least three independent experiments. Statistical significance was defined as P < 0.05.
  40 in total

1.  Infantile hemangioma research: looking backward and forward.

Authors:  Ilona J Frieden
Journal:  J Invest Dermatol       Date:  2011-12       Impact factor: 8.551

2.  Cytoscape: a software environment for integrated models of biomolecular interaction networks.

Authors:  Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker
Journal:  Genome Res       Date:  2003-11       Impact factor: 9.043

3.  Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression.

Authors:  Shoshana Greenberger; Irit Adini; Elisa Boscolo; John B Mulliken; Joyce Bischoff
Journal:  Angiogenesis       Date:  2010-09-25       Impact factor: 9.596

4.  SOAP2: an improved ultrafast tool for short read alignment.

Authors:  Ruiqiang Li; Chang Yu; Yingrui Li; Tak-Wah Lam; Siu-Ming Yiu; Karsten Kristiansen; Jun Wang
Journal:  Bioinformatics       Date:  2009-06-03       Impact factor: 6.937

5.  RNAplex: a fast tool for RNA-RNA interaction search.

Authors:  Hakim Tafer; Ivo L Hofacker
Journal:  Bioinformatics       Date:  2008-04-23       Impact factor: 6.937

6.  Fast gapped-read alignment with Bowtie 2.

Authors:  Ben Langmead; Steven L Salzberg
Journal:  Nat Methods       Date:  2012-03-04       Impact factor: 28.547

Review 7.  Long noncoding RNAs: cellular address codes in development and disease.

Authors:  Pedro J Batista; Howard Y Chang
Journal:  Cell       Date:  2013-03-14       Impact factor: 41.582

8.  Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments.

Authors:  Ugo Ala; Florian A Karreth; Carla Bosia; Andrea Pagnani; Riccardo Taulli; Valentine Léopold; Yvonne Tay; Paolo Provero; Riccardo Zecchina; Pier Paolo Pandolfi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-27       Impact factor: 11.205

9.  Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies.

Authors:  A Munden; R Butschek; W L Tom; J S Marshall; D M Poeltler; S E Krohne; A B Alió; M Ritter; D F Friedlander; V Catanzarite; A Mendoza; L Smith; M Friedlander; S F Friedlander
Journal:  Br J Dermatol       Date:  2014-04       Impact factor: 9.302

10.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.

Authors:  Daehwan Kim; Geo Pertea; Cole Trapnell; Harold Pimentel; Ryan Kelley; Steven L Salzberg
Journal:  Genome Biol       Date:  2013-04-25       Impact factor: 13.583

View more
  8 in total

1.  miR-296-5p inhibits IL-1β-induced apoptosis and cartilage degradation in human chondrocytes by directly targeting TGF-β1/CTGF/p38MAPK pathway.

Authors:  Zhilin Cao; Wenguang Liu; Xiaoyi Qu; Haiyong Bi; Xiujiang Sun; Qian Yu; Gong Cheng
Journal:  Cell Cycle       Date:  2020-05-07       Impact factor: 4.534

2.  Long non-coding RNA breast cancer-associated transcript 54 sponges microRNA-1269b to suppress the proliferation of hemangioma-derived endothelial cells.

Authors:  Zhonjun Lv; Ke Yang; Ya Wang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 3.  The role of mRNA in the development, diagnosis, treatment and prognosis of neural tumors.

Authors:  Yiyang Zheng; Yanyan Luo; Xixi Chen; Huiting Li; Baojun Huang; Baofeng Zhou; Liqing Zhu; Xianhui Kang; Wujun Geng
Journal:  Mol Cancer       Date:  2021-03-05       Impact factor: 27.401

Review 4.  The Regulatory Roles of Non-coding RNAs in Angiogenesis and Neovascularization From an Epigenetic Perspective.

Authors:  Itzel Alejandra Hernández-Romero; Lissania Guerra-Calderas; Marisol Salgado-Albarrán; Tatiana Maldonado-Huerta; Ernesto Soto-Reyes
Journal:  Front Oncol       Date:  2019-10-24       Impact factor: 6.244

5.  Silencing long non‑coding RNA NEAT1 suppresses the tumorigenesis of infantile hemangioma by competitively binding miR‑33a‑5p to stimulate HIF1α/NF‑κB pathway.

Authors:  Li Yu; Hong Shu; Lu Xing; Meng-Xing Lv; Li Li; Yu-Cheng Xie; Zhao Zhang; Li Zhang; Yu-Yan Xie
Journal:  Mol Med Rep       Date:  2020-08-04       Impact factor: 2.952

6.  Microarray expression profile of mRNAs and long noncoding RNAs and the potential role of PFK-1 in infantile hemangioma.

Authors:  Kaiying Yang; Xuepeng Zhang; Linwen Chen; Siyuan Chen; Yi Ji
Journal:  Cell Div       Date:  2021-01-11       Impact factor: 5.130

7.  Circular RNA expression profiles in the plasma of patients with infantile hemangioma determined using microarray analysis.

Authors:  Zhiyu Li; Yimeng Chai; Zifu Zhou; Xueqing Li; Jianhai Bi; Ran Huo
Journal:  Exp Ther Med       Date:  2021-04-15       Impact factor: 2.447

8.  Long non-coding RNA ATB promotes human non-small cell lung cancer proliferation and metastasis by suppressing miR-141-3p.

Authors:  Guojie Lu; Yaosen Zhang
Journal:  PLoS One       Date:  2020-02-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.